Seres Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Seres Therapeutics's estimated annual revenue is currently $155.3M per year.
- Seres Therapeutics's estimated revenue per employee is $270,035
- Seres Therapeutics's total funding is $402.8M.
- Seres Therapeutics's current valuation is $738.5M. (January 2022)
Employee Data
- Seres Therapeutics has 575 Employees.
- Seres Therapeutics grew their employee count by 0% last year.
Seres Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | President, CEO | Reveal Email/Phone |
2 | Chief Financial Officer | Reveal Email/Phone |
3 | Chief Medical Officer | Reveal Email/Phone |
4 | SVP & Chief Information Officer | Reveal Email/Phone |
5 | Chief Technical Officer | Reveal Email/Phone |
6 | VP, Corporate Controller | Reveal Email/Phone |
7 | VP and Head, Medical Affairs | Reveal Email/Phone |
8 | VP, CMC Technology Development | Reveal Email/Phone |
9 | SVP, Clinical Development | Reveal Email/Phone |
10 | VP, Human Resources | Reveal Email/Phone |
Seres Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $12.7M | 82 | -45% | $107.3M | N/A |
#2 | $0.2M | 1 | -50% | N/A | N/A |
#3 | $6.2M | 40 | 21% | N/A | N/A |
#4 | $42.2M | 218 | 4% | $165M | N/A |
#5 | $14.6M | 94 | -37% | $312.8M | N/A |
#6 | $0.3M | 2 | -67% | N/A | N/A |
#7 | $235M | 366 | -5% | $340.9M | N/A |
#8 | $56M | 289 | -7% | $7.6M | N/A |
#9 | $4.7M | 61 | 36% | N/A | N/A |
#10 | $2M | 13 | 8% | N/A | N/A |
What Is Seres Therapeutics?
Seres Health is a clinical stage biotherapeutic company focused on discovering and developing Ecobiotic™ therapeutic products to treat important diseases by targeting the underlying biology of the human microbiome. Seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. Current candidates span metabolic, inflammatory, and infectious diseases.
keywords:N/A
$402.8M
Total Funding
575
Number of Employees
$155.3M
Revenue (est)
0%
Employee Growth %
$738.5M
Valuation
N/A
Accelerator
Seres Therapeutics News
Seres Therapeutics (NASDAQ:MCRB shareholders incur further losses as stock declines 14% this week, taking one-year losses to 74%. By: Simply...
Seres Therapeutics, Inc. (NASDAQ:MCRB) Receives Average Rating of Hold from Analysts. Posted by admin on Apr 19th, 2022.
Seres plots for a mid-year approval request for its C. difficile therapeutic, SER-109. Related: Seres Therapeutics' Oral Microbiome Candidate...
Press Release | Nov 10. 2021 07:07 GMT SER-109 has the potential to be the first-ever live biotherapeutic product (LBP) to be produced commercially; the collaboration with Seres Therapeutics is a critical milestone for Bacthera, a joint venture between a Lonza Group Affiliate and Chr. Hansen. ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $182.5M | 577 | 1% | N/A |
#2 | $237.4M | 579 | N/A | N/A |
#3 | $108.4M | 598 | 16% | N/A |
#4 | $108.4M | 598 | 6% | N/A |
#5 | $187.9M | 604 | 8% | $109M |